p>“Envera is continually isolating and testing new environmental microbial isolates,” commented Matheny. “We have taken this approach because most of the strains in publically accessible culture collections have been extensively tested, and those strains with positive attributes are available to everyone,” added Matheny. “Envera’s approach is to perform our own microbial isolations to build a proprietary culture collection containing unique organisms with extraordinary attributes,” continued Matheny. “Discovering a group of bacteria with exceptional capabilities, and that may be a new species, is further validation of Envera’s business model,” Matheny added. “We are preparing additional patent filings to cover a number of proprietary microbial strains we isolated over the last few years,” concluded Matheny.
Envera is a bioscience-based company focused on the production of environmentally friendly products. With decades of experience in the isolation, large scale production, stabilization and product formulation of microorganisms, Envera is a leader in the development and commercialization of microbial and enzyme based products for the consumer, institutional, agricultural, waste water, and bioremediation markets. Envera’s technology platform includes expertise in the areas of bacteriology, mycology, enzymology, and chemistry.
Contact: Michael Matheny at mmatheny(at)envera(dot)com or phone 484-593-4002 for more information.
Read the full story at http://www.prweb.com/releases/2013/11/prweb11349076.htm.
Page: 1 2 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Envera Increases Scientific Staff2
. Envera Appoints Michael McErlean Fermentation Manager3
. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie4
. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date5
. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case6
. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration7
. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 20118
. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial9
. Ronald L. Chez Files Amended 13D and Letter to the Board10
. China Cord Blood Corporation Files its Annual Report on Form 20-F11
. Regulus Files Registration Statement for Proposed Initial Public Offering